0001104659-22-080678.txt : 20220719 0001104659-22-080678.hdr.sgml : 20220719 20220719071026 ACCESSION NUMBER: 0001104659-22-080678 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220719 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220719 DATE AS OF CHANGE: 20220719 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 221090326 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 8-K 1 tm2221345d1_8k.htm FORM 8-K
0001012477 false 0001012477 2022-07-19 2022-07-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 19, 2022

 

 

 

AVADEL PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

 

 

 

Ireland 001-37977 98-1341933
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

10 Earlsfort Terrace

Dublin 2, Ireland, D02 T380

 

Not Applicable

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +353 1 920 1000

 

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered

American Depositary Shares*

Ordinary Shares, nominal value $0.01 per share**

AVDL

N/A

 The Nasdaq Global Market

 

*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) Ordinary Share.

 

 

** Not for trading, but only in connection with the listing of American Depositary Shares on The Nasdaq Global Market.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On July 19, 2022, Avadel Pharmaceuticals plc (the “Company”) issued a press release titled “Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information furnished under this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.  

 

Item 8.01 Other Events.  

 

On July 18, 2022, the Company received tentative approval from the U.S. Food and Drug Administration (the “FDA”) of its lead product candidate, LUMRYZ, also known as FT218. The tentative approval indicates that FT218 has met all required quality, safety and efficacy standards necessary for approval in the United States. The final approval of FT218 is pending disposition of U.S. Patent No. 8,731,963 which is listed in FDA’s Orange Book.

 

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.  		   Description  
99.1    Press release issued by Avadel Pharmaceuticals plc on July 19, 2022
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

 

Cautionary Note Regarding Forward-Looking Statements

 

Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to the Company’s future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to, the timing and receipt of the FDA’s final approval of the FT218 NDA, if at all.

 

Any forward-looking statements in this Current Report on Form 8-K are based on estimates and assumptions that are made within the bounds of the Company’s knowledge of its business and operations and that it considers reasonable. However, the Company’s business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of the Company’s business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in the Company’s forward-looking statements include the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission (SEC) on March 16, 2022, and subsequent SEC filings.

 

Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 19, 2022 AVADEL PHARMACEUTICALS PLC
   
  By: /s/ Jerad G. Seurer
    Name: Jerad G. Seurer
    Title: General Counsel & Corporate Secretary

 

 

 

 EX-99.1 2 tm2221345d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension

 

- Validates the safety profile and clinical efficacy of LUMRYZ

 

- Pursuing strategies to accelerate final approval

 

DUBLIN, Ireland, July 19 , 2022 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to LUMRYZ, also known as FT218. Tentative approval indicates that LUMRYZ has met all required quality, safety, and efficacy standards necessary for approval in the U.S. Final approval is pending disposition of U.S. Patent No. 8,731,963 (the “REMS patent”) which is listed in FDA’s Orange Book. LUMRYZ is a once-at-bedtime investigational formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

 

“We have reached a critical milestone, as tentative approval confirms the safety profile and clinical efficacy of LUMRYZ for adults with narcolepsy,” said Greg Divis, Chief Executive Officer at Avadel Pharmaceuticals. “Tentative approval is an important regulatory step forward and indicates LUMRYZ could potentially be granted final approval in 11 months or less. We believe once-at-bedtime LUMRYZ offers the opportunity to positively transform the lives of oxybate eligible patients living with narcolepsy. Our extensive market research indicates Avadel is well-positioned to capture significant share of the oxybate eligible patient population which we estimate to be in excess of 30,000 patients. We are pursuing all options to accelerate final approval on or before June 2023 and prepare for commercial launch.”

 

With tentative approval now secured, Avadel is continuing the following actions, including those that can potentially accelerate FDA’s final approval decision and shorten the timeline between approval and launch of LUMRYZ:

 

·Filed a motion in the U.S. District Court for the District of Delaware on June 23, 2022, to delist the REMS patent from FDA’s Orange Book. A court order requiring the patent holder to delist the REMS patent from the Orange Book could provide a pathway for a final approval of LUMRYZ prior to June 2023.

 

·Preparing for a claim construction hearing (“Markman hearing”) scheduled for August 31, 2022, that the Court previously stated is needed in order to rule on the pending patent delisting motion.

 

·Continuing key activities in anticipation of final approval, including planning for the final preparation of the LUMRYZ REMS program and the continued manufacturing of commercial supply.

 

Based on extensive patient and physician research, Avadel estimates the total patient population could be greater than 30,000, and expects LUMRYZ, if approved, to be the treatment of choice for patients suffering from narcolepsy-related EDS or cataplexy. The current twice-nightly U.S. narcolepsy oxybate market is estimated at $1.8 billion comprised of approximately 16,000 patients. In addition, Avadel estimates that in the last three years, 10,000 – 15,000 patients have discontinued their twice-nightly oxybate use, many due to complications associated with middle of the night dosing. Furthermore, based on an analysis of U.S. claims data, the Company believes that each year approximately 3,000 patients initiate oxybate treatment for the first time and expects this to grow by 25-50% over time with the introduction of LUMRYZ. Based on the estimated total patient population, the potential market opportunity could be in excess of $3.0 billion annually.

 

 

 

About LUMRYZ

 

LUMRYZ is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of EDS or cataplexy in adults with narcolepsy.

 

In March 2020, Avadel completed the REST-ON trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, to assess the efficacy and safety of LUMRYZ in adults with narcolepsy. Among the three co-primary endpoints, LUMRYZ demonstrated statistically significant and clinically meaningful results in EDS, the clinician’s overall assessment of the patient’s functioning, and reduction in cataplexy attacks for all three evaluated doses compared to placebo.

 

In January 2018, the FDA granted LUMRYZ Orphan Drug Designation for the treatment of narcolepsy based on the plausible hypothesis that LUMRYZ may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for those with narcolepsy due to the consequences of middle-of-the-night dosing of the approved product.

 

On July 18, 2022, the FDA tentatively approved the LUMRYZ NDA for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Final approval of LUMRYZ cannot be granted until the expiration or other disposition of U.S. Patent No. 8,731,963, which expires on June 17, 2023.

 

Avadel is currently evaluating the long-term safety and tolerability of LUMRYZ in the open-label RESTORE clinical study. For more information, visit: www.restore-narcolepsy-study.com.

 

About Avadel Pharmaceuticals plc

 

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

 

Cautionary Disclosure Regarding Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to, the timing and receipt of final approval from the FDA of the LUMRYZ NDA, the results of the Company’s efforts to accelerate the FDA’s final approval decision and to accelerate the timing between approval and launch, if approved. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions, and the negatives thereof (if applicable).

 

 

 

Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, our business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in our forward-looking statements include the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021, which we filed with the Securities and Exchange Commission on March 16, 2022, and subsequent SEC filings.

 

Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. We do not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

 

Investor Contact:

Courtney Turiano

Stern Investor Relations, Inc.

Courtney.Turiano@sternir.com

(212) 698-8687

 

Media Contact:

Gabriella Greig

Real Chemistry

ggreig@realchemistry.com

(203) 249-2688

 

 

 EX-101.SCH 3 avdl-20220719.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avdl-20220719_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 avdl-20220719_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2221345d1_ex99-1img001.jpg GRAPHIC begin 644 tm2221345d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jul. 19, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 19, 2022
Entity File Number 001-37977
Entity Registrant Name AVADEL PHARMACEUTICALS PLC
Entity Central Index Key 0001012477
Entity Tax Identification Number 98-1341933
Entity Incorporation, State or Country Code L2
Entity Address, Address Line One 10 Earlsfort Terrace
Entity Address, City or Town Dublin 2
Entity Address, Country IE
Entity Address, Postal Zip Code D02 T380
City Area Code 353
Local Phone Number 1 920 1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security American Depositary Shares*
Trading Symbol AVDL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2221345d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001012477 2022-07-19 2022-07-19 iso4217:USD shares iso4217:USD shares 0001012477 false 8-K 2022-07-19 AVADEL PHARMACEUTICALS PLC L2 001-37977 98-1341933 10 Earlsfort Terrace Dublin 2 IE D02 T380 353 1 920 1000 false false false false American Depositary Shares* AVDL NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://avadel.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2221345d1_8k.htm avdl-20220719.xsd avdl-20220719_lab.xml avdl-20220719_pre.xml tm2221345d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2221345d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2221345d1_8k.htm" ] }, "labelLink": { "local": [ "avdl-20220719_lab.xml" ] }, "presentationLink": { "local": [ "avdl-20220719_pre.xml" ] }, "schema": { "local": [ "avdl-20220719.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "avdl", "nsuri": "http://avadel.com/20220719", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2221345d1_8k.htm", "contextRef": "From2022-07-19to2022-07-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://avadel.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2221345d1_8k.htm", "contextRef": "From2022-07-19to2022-07-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-080678-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-080678-xbrl.zip M4$L#!!0 ( $PY\U2I*9M30P, "D, 1 879D;"TR,#(R,#$ T-A9^12@6 MH,'#B&*%M2-=J0H.;:_M,E3'[.O<0N5G_U'='3=Z-X& M?Y[;!R^_AA,57I2[#^%1>>J+P?3X:=BXNRA?NH_W/_UOZ9(UZ0]PB( ^#";K MELDO2V]X MNTCBF;+VD@UXPJ1"S'^%#]2,L @^=%+G*R@IA!ZE4))# [R$D]BW^WSD:(?& ME[R7+SDTEK"/4#2#]Y#L)K*9(X%#UX-E+Z=(H5;AVE@,A6H:85E(2%T%M$") M)=JKG=1NQ[@-TS7,THR)1@&=D= (!9B:^C;(DGOL57274AQBIJZX""]Q#\54 M)_,2(TIZ! <64$CTL3(%*R/DXXU:>&#S53)%7! M*;[300,ST$U9I&Q<3H/K:\4")*A;Z=!H:,5$)< ]PDBR5-9['H"FTV*3E!XF ME)JS#%Z0B"4.;MEI,HX$EIJ7Q-[2AHR80=:0?$3]F.[&F8=22,D,^1[-=RWO MKS;N@:0OJ^;@ZY8DYF:T,MM X%[=,FC6SA M7 ()?T5EY=[0(CS"0A%=V N70QHZ48;^8V$98-:1%G#^1SCS_LCFRSU4T^ERH0!;:<5-MVKZ'K2XGTAMH)@9S'G0F*!7TE>0 M/9'!/-)=@ICOP&Y!Y+P]@EA[MQ=%(-<3S!"FPVV7WOA.;%R^D.E@JF1N@7.M M?<)9?57>$4\BMD= ;S]8ZX)ZBYG,Y5XEXO.8*3%-,MRR2!8I^239CIU/9OD/ M8;M#R5GI@9B?AG<41_$_Q[Z!K"^-FI-JZN%?4$L#!!0 ( $PY\U1MA[#= M_PH &R' 5 879D;"TR,#(R,#&ULS9U?4^NX&<;O.]/O MH*8W['DP$YF6: DYVS;GFU# MIY*X@& ]K_S(^D62_TC^],-NDZ(7PK.$T?/1].CC"!$:L3BAZ_/1U\7X8C&; MST4Y(3D5#N^ S]]6AZLD+C\8!\OQ$:,_[U M?E[G^YCGS]G99/+Z^GI$V0M^9?PI.XK89EB&BQSGVZS.[>/N8_53AG]*$_IT M)G^M<$:0.%XT.]MER?E([K?:[>O)$>/KR?''C]/)/WZ^7D2/9(/'"97'+2(C M%25SL<5-3T]/)T6JDAK*W8JG:A\G$V6GSEFD)AWZAI,L.]CT^F1[LL'JF#7QQ!SE)R3QY049;T8ZMWU#WG?$#W'NC[1H MY\G[CG0C\O]B.SBT\MBV27BPZ,Q,JDS**C!2[V4'0,5=YU M[BQJY9O*UIQQL^RR9RSRS$ATM&8ODY@D(N_CZ7_^(C^.RX]%T<6_O\V8& U< MK+*Z+:F\X,H;YE%/ 2O%)&*B>WK.QVEY*,OP!\XVUMU6 M)6>6Q-_251U?'AJQ"\!H2\9)QK8\(F^JF:9;Z"A5CC:I4,AA%:'CKXO1]X4& M_:I4__XT.>3BJ++%4&B[(31?BEPMI6@GNZIJFRE5T\VT("K:8DBO9R5!4N.A MDB_$SF-IX"K%:TL1M'17U6RUI>JYE1A$1=L/(LA_== M96G)G%>\Q:11_PU-6!B8QF :&EJ/C?P]62>RJY$VY#DOD1L[FC1 [[H;Z+2M M]PM6<1#@#'$(]AS-(%1'>63I@M(M3N_),^-="+5EKLFQF=2!:6J"XL1B#,2C MU*)2[)&*OV_%V3SAZ;X7#$/IF@W JHZ')@N*$+LW$)):[I^3)<L:$M"N#HHA# H6R!T(3!F@N"E"O$/S3X+Y M,&0:2C_ &%;MN-2R &'1O?6A(O7>0)EM.6\YAWL?6.KL9FZ/V?J^+J + I8> M<\;=WE+>@L5C;W1)\R3?R^?Q;K:;%>&6 IH25WQ YA07>GH0/ "F= Y*&9(Z M5 J]U;ZZJT!S^2 D6"1=YI8"N\DV"6U-0#18C0%$'+3%J)B)5HKC=$YC MLON)[,&R&3JW7 VVV!HHH#(L#L#T*C$J% C(?<&QQU/-ICO%TG4TVV80K=X M0$;;?.BJ@ !K &$5&JTF,]\]RI+O)O' MCD(2F?+^\A!=2[!:;'=IL;0!P0 M/MT. 8I$$&I'^89I3B/&GUGC<8D9VXK&<#]C,3QBZ8ER"]:@(K3QZ@P)"+(A M/@'46J$?RF=:$)-S@XH,D,S!&W47<2P.5E;]N4XHF8+'P*IU2UB'W397%F% M-,'N (8JY0?U VYR9^'C+E^S5]L WJ/2"C6G5"LU!%AXRAK<^8&2 M'-_($-^H%(.M6W['V4M"(W@8#U:9NT-S6E)CQ0VL9Z&YE2[1N+.Y;E./U7\MQYDFX7>T'$:M@*2DL9 M'BXV>WW0E#%(!/DZZ:ZPE3= K-/5M'1W4XXMM@Y3CAN)08!@4$ RU#.]E915M,U?7<2 NCFDU#1BT7WV^A\?6%EBO+I'>/C,(/%Y@2 M5[4-F5,UKJ<'4>N *;WF"QDJ=!ZOW,L5+C)[4]Y(<];3ZW;JCETE!%'#NANC MVU;I'FKT%Y[D8N\SMMEL:75GR/8,(J!S5=.=-E6M6T5!$-#E3*>ATJ*VV ,: M"Y8F49(G=/VS.#GE";:5S"9R!05L4!%A*H+ ;2ELW 0(J7T ,(=)Q)&(BJC MF' H%SGBMP\/UMZ_2^P*C'[#"A!8&00HO?9T8$3 .&I$H#($%3'^T9EGV9;P M-P%D"?&$$6@>@,G0AX@49+(7K#+0-U\+$FU%?[F?'J^629[:3CQ-B;/^"3!7 M]TY:>A!\ *9T'HHTQ![0]/A/JS\C%>4!@1NVY%@N:KO8;U8L!5;"LJI<@=!A M4;%@D02! ^Q+)^*&H4J*2JVOE;):ABU%TM)=06"UI:J_E1A$Q=L<&8U J[X] M-O^7N^A1&"/ 9 >[S'4W8#.I=P5-31 8=!@S3E8J*5):7Y,=#EW8NG]0L/8V M*%CW# K6(0X*UD,'!6NO@P*UZW*9$M%&W:[29(V!11,[U:[!Z+"L,V*1!H4+ M[ ]L.^H0=(CQL=IFL>R:?)4 WQ0>KL0'2TD!G;/U-KMLU@MNVD1!<-+ES%AR MLUP(KR%&4NV#C6VG1A\'1,),& M4F686F.Q#CPLP^GCLGOY$,;W%=G>I6^_VJ9L>V^T' M;P!Q$$@-<0@\?B.#QD\R"JFPZFJ9-YJ^L71+<\R+.>SL)G%VF]9F;-FU &'4:!.=JUC%R MN1JLN/*Z; V?B>'7FG4\?:ZIW"]>8U@TUZ^I)0$A8O/5L8H-1TKKC8?%!J?I MYVV64)+!G9*F"BE26F\\7&X(7XON[D?.7O/':@U9 ML'R VBT?G9;;G%BE ?'2Y0_@1H6@,D8M^^L/H-UA ?1R!4BXM!:I8W1 LQHW MABXD:"!S!C$IB>3UF!N6HR5#7S."\D>"+JO7ZC57KB_S\?F6E"B2$R[*T3J- M,;=AU"5V_L84T+#QWA1#&01,O?;@=ZC4$4B%>"#G5K#,F^=XA9%Y3C;@3(K^ M$%<4#36O6.K3!T'40),Z5T58^\2["$0RTO>J2LT%^>%A7TOD>+1L,:@-EAN* M(#@!;4%#Y>;[#?RMY[==I4ETE3(,7X5I:1ROXF?:TQ;P.P@"HL!T!2W;5PA1 MH?3&P&=,G_CV.8_V=YQ%A,BGM;*ZY>J[1CWQO"T[K$Y(XL_[>_) N)S3L"2[_+/8V5/' MF<> 6-=G=8.+HY_D]08& >);W4*G@!EJ9H!6\CFS*@OTJ\P$%;G8WM/>W'0M M/HG-:I/XM<(9$5O^"U!+ P04 " !,.?-4_.3J.U0' "]6 %0 &%V M9&PM,C R,C W,3E?<')E+GAM;,V<37/;-A"&[YWI?V#5LR1+3IM:L9NQ%2NC MB1.[EI*TO60@$I(P!@$5 /7Q[PN0HJ(/ EQ?LO;!ELD%L.^S$,@E %Z^7:<\ M6E*EF117C4[KK!%1$3WJ#X>-2!LB$L*EH%<-(1MO__SYI\C^ M7/[2;$8#1GG2B][)N#D44_DF^D12VHO>4T$5,5*]B;X0GKDCF*YGBA>MG'>+MW9U6S/ MLH#]GB>:]73NWIV,B=UEHGC1)^3E!)3A_I M-')_;?1VK9(E22AWX6J[4^V^M-W1^ID7FBLZO6J09<)MW=WNV>O.A:OYUP,C MLUG8;JF9ZU6-J'W0ZD)1387)A=[9 P=%Z-K8SD23LB+7/LPOPXPSW7:43M1T MO2I+;4OV8V&Y=:-TA,OXH&WNZ,LCH65/SAEK&K=F)C M3L'^^RUO['JBC2*Q*6OC9$)YWL8W:W-DTOY!GI5$QK;6:L<.+8[]V@_=M8HC MJ1*J+/.R+J+B@X"==LZM17M!E*VH&<\9W\5ZJF3J([2E(3V.[L.R3?PXHM?6 MA\3Y,>!D5HWTR 3(M(,!M5(-)M5W5,>*+1R;&K@'ED#&753&%=H04)??HT(H X9]CCAI!M8A1N!8B(_R1+J2J@7]H"63^"I-YE39$ MU']E1!FJ^ 9"^\08"/PW3. >A8C,QXH(S1PC"/13:R#UWU%O2#P:$;&/YI1S ME^(1 >KM5?9 ]*\QT?MUOA#XMTMWW;>7&SC_O2+ $/SQ4D)PHA8Q"@]4,9G8 M2[T"\#\Q!I*_P"3O48C._%8D4.([4W".A _\2!XB[@'3,>&%5P-[3(>15YA# ML:/DIK4RT='_0XD"@]\SAF)'25=K)") [V=*'3@4'&'\UE#L*(EJG4@$[K?" M,+-Q\P6?LG3R_<'K(>]3*RAGE.34)PJ-;_ED0A@W%1)B?&P)Y8R2DX;$H;'N M6TV*\*%(Z/H#W81@GYA"::/DHD%Y:+@?%$N)VHQ87#^ G-I"@:-DH&&!:,3' M9#U,K#(V9<7$8CUX;Q$H?Y3T$R07+0Q#$4NUD'N/F_LRL]_-35\FP2&^IB T M)"AYZ3.DHP7F.DDL,KW]<\<$[83"46D.GFO""T) Y@M"WWT>^BX*_&?>_6@Y)(5 MZZ[JR)^4@.)'3&7#8K%CL+WX0WI]:0EECIC65HO#9OT@M2'\7[:HN\NLMH=R M1TQP0T(Q'DP6\7+8C+ M-,W$]KF.9X;-8PI%C)(F!N4AX!Y)SF)FF)A]M'>0BA%>S;K*#@H:)2GT"T.@ M_*"HBSBUM^;YFC&WYT'=3Z>^D3AD#Z6.DA/6"\6G/]0ZH^JY,:@H!8T$2GH( M%8TQYM XL\/@IM.=C-TN'L^(*N/V#HTTZD=R_5:72 M$$H9)1$,2$, ?>!+->(C$RA!_5"-WF,*A8ZSA3,D#P-WEC!#D\*M 1-$Q#;UVNVY\V3R]:6@0<#9 MXPD4C39%\)5R_D'(E1A1HJ6@29$.A&8)O$6@D4"5@,)'G)0,BT5<"V>H\YLMZ3MB MR-;+4 Q\): Q0)R@#(M%7<.O^O9B-)/AN?@C0RAQQ"6XE=+00(]2POE-IIF@ M.CC.'!E"02.NM:V4A@;Z-J5J9@>Y]TJNS'R[_S0$W%, "AYQ16U0*EX UM_W MO1=[\X+T*ZS!;U1 1.\5B?G*D#AV"S6**[Q(B/*0#]E#V:-N_/0+1:!_;^94 M[=];Y0X-;7X76E!17PH:"92T%BH:[WJ[]_:!X.7VP [*'#&!K1*&MX\KFW 6 M#[@DP?OV S,H8\1LM4(6&N(;(IY4MC#QYD')F%(W#:-WWSQ T@2L !H6Q#SV M62CP'BW(-'4;G&3\-)I;X?H^,_D;6JV/P0<,P7+0\&!N,@4(1[P[TM\WH-'D M9O-(IU2Y)1!CNC8WMK&G\,T2H#@T1JAO1@)CJ C59?M$UYT]X-[#6YQQO]R[ M9NV1_P%02P,$% @ 3#GS5+"M3P];& CH !( !T;3(R,C$S-#5D M,5\X:RYH=&WM/6ESVLJRWUWE_S"/^\XIYX1-@!>PPRW,XN %? G)ZY3Y1JD M 10+"6LD&_SK7_>,! (D8SO@.*]REQBD67IZ>N^>X>B_XZ%![IG-=5@=L2!.ZR1UJJFS:R=#-V^CQ\>VT:=:K,.P<9[*?ERKJD3VG17-G7\ICJWY,![*7CK M-W1YHD_I:-JX1WE7-/1>B'$3:24 -;RQ+8/QT#[B34@GS;$3SF3$>#A8\#J% MK[%G&GMFICU5RS4=>Q*^,:5MZ3S5F)%5KB"TS MZ7TE'Q.,RJ@&?PG^Y\C1'8,5CU+R+[P=,H<2'"'![ES]_E.L;)D.,YU$!Y83 M(ZK\]BGFL+&3DOR8VSM;N\&%WLP6>.,O\ 6CY&K37J_IOKM_PX!. M 7KX7]4$_$W*@!B;&G538^,S-KE)@RQ+*YG<_OY+QLT'QBT-F:G!_YV:0?LW M/6IP]H*A]I6;=O.F(X?ZM\)&3DT':H8O.O(S.8!/9Z1LH7 G'38<&=1A_-^/ M'S_"BU:SB3VK!L/YX1,\_E>NLVY.A< YR(:ZPX8\"3/R%\"V=PP44+E1;CSQ M)X&$1R\9(W/3'E";\9O,C9#V$RRHZ?=^/TWG@/=)@9B6R<1+ M?5Q 7F(V,JGXIFL:,P7+XE=HV'"',)8JN7'LM% ZUFQKB'2<2.\GE+QCS3[' MB FKAJF87@BEU%AQ1JI'J;DI?F16226?8J!>"ET+!"DU!0D'X9FC\%A1O \% M(36'"(0(I#ZSP11A7+9 ]5+@PFX T(@P!@H#H3E07"1\)D^.N1;S7J.,_A3C M.M ^DX+,FVI^<#D=MUS;GPV:":HH>,@@NO8D,GR!ZW=C8A^F3Z?/=0W?]'1F M$[$4%JJ4R_6S^3U;[#R;+A4ZGS?;"/!K: _]!#Z3R>75.72 :&7,+FD%'NVJSH<6X!VOB#^:_FI\#1(L:7 M8B!R"@\)HM&KYYB)FZ5Y0#3 -B[C%OL*AJ".90=>OQP'BS"&C1J8M,),:ZB; MJZ9=C9?%><,&]M_/86$)H1Z'!OA1B@=?:AZEH#_\Q?\>C7Q).Z1V7S<+)!TK M_OD?92]]>)0:%2.;3%\&-$C+-5CBDO:%$@X*<=DOX5BC LF.0,UX#[J6XUA# M[]F#KCD#5!'I/V)SO;N6#7#+WL<&56])!K0(MPQ=.R3>2W\D^5Z9O4>]D^#Z M(V@U>#I;&F+ ^S>P@M3<$EZ,G^G'!1]0,CNS!N!N$$=M$;TIN-2#+,T^%DO=\L]?]W4[I%T"JM:J-#6M7+9JOSH[+U1]@X"BN*:'#IVMRE MIK.]Y5@PFXI>/%&RQ+)GWW9WM \A[/6^%F+UB#-@"+1KZXX.0%3'ZH":0'4E MU2'P6LEG,@D'-N$/8/0Q);/&>X:YW MBX4E'7"PH ,NA==6E3Y=N#(XZ'ZUVNZWAS.FO5H9!.,'&LPTA'X#C4XF #TS MPY3%'&"QXJEK3( *X@1'C=0?OR15_-84+\+%"H0?K$L+1'&.#+NU6%_GF$5Q M, P9SCB[U3.CT6W+IVWR>5Y M^1E&UNMWZ$FFB$3I3G5,09[CFE!RV=.U$,H)'S$5 U[:]I8.>'S6\N?O_VGD.[!H,!# .>JR)GG8Z)[R.J:?[W%P,;0.LT1*-:AD%''.#Q M/XEPOF/[P]\SV]%5:OC+ MS[X;\C1_-;>4-GLS"R!V/"UOL#@&PWF4-&\9\: MK#=[^!)\*?,6UDQ<9>?$5=U4+1L, Y'I:3N@4LLR/5FVM CI=396JQ8_39^7 M;]>A]C$K76!:G]HCV[KWDJ/SJO\9H,:*=9L9U-2>E&[>1T>+WI+<3]B2\MR6 M8 (/H.\R.QS_M?1Y(WUG5[YHKS>[%G$[FQ-S#DHBNY]?3A.]%)4_@[HKH@FR>PJMU?JJ4'\_/=L_S:\-K! "Q8OX@H61SX+UDGXEE^,=^C:C9 MZ ;L"#9$O]("/\TFW\%-XYHN7,PG262S4)6MX5#G_.<"46^U274X,JP)L]_] M1H+1I0?%ZX>?AS@4142RR4^$8IYK2<-*?@C;Q)2P/8IKL(:63,U?SZIYP89X M4.P*BW63AN1,,^3F-$-)TVS&N?<'2UR4<*V@?*X^YBX.KF^O]J7"68]B")D_ M5E32LRQJE=H&%N(!*IAM4W6I8F).08R"^=>-Q3^C\@9S2RK#QZ;=L1[,"(2F MCR\[NY=[Y<'WM:G9I:ECQ8K;-F 2E?)AK#B+-O[YGX.,LG_(M[<<9K#1P#(9,87U%D>3TG 1 MYX3:C()HT%C!0QJ*WH]1H0F4XR7H$2V!2O]4\K5*=;=VIZQ! @7GBQ6SNT_Z M9%W*F MKXLGH]2C2U+OS2'9J0&[@%LLX]JVT/+PE4H1%]_>TGM$IC-!= &S,&)0[F?J M/BR#_)PZL7>W@YL29[%B>) M,]+3#91%.@?!Y#!3PXR"8P'FAZ[A4)-9+C.(+3' M%X$,A0L#P9Z:$^)EJWO@0UD/V \#FCJ&(7@AJ@[Q94G$F4\8] $7?<0?\PF? M!=?K8][I9&97-VR* Z#==5E$].M2-28%\A24C&OB+&LWD=L:3VU]MW0&* MP+B1:WH^/P\7WM?5="7[<)PM95[OOCRG:#X4)(FV@\-(N3[_)XC;HC<@ !D< MD8R\6A&D;,SQD%QFUZ/IA=(+K+C84?9)N=8BF6PZ"0T_1-@^O^ETO73JQR[: M(.=5V VS?P&B#N2=$4ZDD_-3:^^JT71;O8T2Z3(\/T*AL]%@+^5PR^2IY&A" MR00H=*XB:$J?N712MOQ-HF]#HKX)?&DSE%EXK$:4=J*>M9N]7I0QW)G0;O/T MS*CQUU>4/H=4H^'Z$9*%41-J8-B5TE7):8G,3O?#\PA8MOU-PF]#P@?A)%SG MW&7V2D+^?MPUOSN/ZD%^+6' YQ+R$G1O2\Y9ELCMJ,\C9Z]M%#EOQC.+#N?L M;Z""^!5.8L#"DEX%L\$=#&+:J]G=WE*$Y/#<#$!OB%?Q)K4XRJ]1BQ-<$@;] M#LFB;)*;$R*>Y!0A+K:WB@(>WYJ"E5/^F*^GBHY-/!E:[. !?5FZJPZ(:E#. MGXQS/EG?Y;WT8J!1KR-C":$+S637M%";BK!@>S+L6L;.BG#NFR\SN[>>93:\ M>D:QG"=?(PUK>R%Q$'GD M]Z\G*]$WC+6F#7LT@R5.Y!E<@]Q3PV7;6_^;3J85,L+CY]C@K[^B,VAKY*Z? M0"Y5CUP\<2.E380;TJO_KUKSV:\PMC>U%;^13"! M!BQ '"G(XJ3K.H!I8T)TC"";IG>,\$%W!L(;,<""@8;;6V#N/$$)T"6*.]:W M8V_K\DTGK9L:.LH,J5L5J2EH< NV'A.UL0MI(YT3 !&\;!P#\-:WK0? )3C< M(\PE44XTUM--8!; N S,IW?)\H'(V3G(+-G!I>T?BN"\WU@7QV5&>%P&4Y#2 M:\]T$YGEL;:WPDY73D=%%W[6,3#N.G=NH\)*Z+A8L>HAG2S@?/.1)5GJY,]_ M(J8OR]G#51G[TK;VZJ6NT7B]"?NR?72.X^@6R$$C:A:M=Y[X\2C!R\\ Q>J'$=N!CHIY_1"\<53G$([>]< M-.=@6#F?<"R6EQ[I.@0Q*[&X@-H]X0\L7UZTZ%@(\;#D?,2\4D=Y3]02<#:C MMXDN QZ$]B.QHB! >Q%;'0%0R&3!G5G/IKP@NHSQFTUP3K>(5T&2?8P@M%C? M-6193*U"*CI7#0OO DNNM;YL4[<9Q8I-D\S='A G)7';*+D$8W5(5>:*T4,7C)- M$.HJP^LY38>**M<2UC/=@\0'P7U^=='Z=@UCY XRAV2'6YKN#HDUGG1!,WV8 MJI>$-RE8X#9TY"X?,1-KCY(>F*0$NF8TK5*:AQ2LN9YKFSH?X#+PFHV!WM4= MDL\G%5GS!"W*KFUC4DC>-(&VO%]:]1XMP!59(71#]-DEIX'E^ZDL6/&4UH.U MK'.XH8X#GBKT A.?.58<0VJ&(6P \'@U!K;%E !Z.E"#OQNH^T%A@X/$1+'S M5&$?A!CY879Y'/>)#J5M$:3.8&.?1./3,WH/8%, =72_PWQ^-9NATZYNR*G$ MY!1DM >/:=G>FO3@DF:GQ:0[/[U+$]T5-&*\TKG(2B+/9PFN0@"Y:*?$,7#. M1N(F #865(M%>DSXIV PP=S>!0'J/!#<5<&<\N!(DC4+D=7WLKSM;#@/\:7S M 4KGIO ZJWCW"Q<2F%-S M@5!5&$3'JVGBGB@&DC6X16Y-Z\%$JJQU,LI!4L0UEL'".RND$\$E7XG6PE\8 M @TC7]EX"3?F?.]<4-X.^!V<]I@S$= S/.] U=P'N!PDN*Z\&SC^0@ MOI]5XOF]K)>Z@IX8\9'1"0^#> J -&W!N,>6=9N<4=I[I;;G&+>[;V[HV B%]\R!]0=^LNB7AY:/7 MIH$ P=U#$?Y&(>%9)#P9<6D WJ;[?A,*L>*.]F&ZALU9DF](8%%DM:+>9,JI MW45I\JJ[,3R4^F4&0I CA2P$P.YOP0*!$WA_O##-@!&1SNYIRP\;Y?$))#ISAE" P"YB _C95 MH3.3J%VU/G01%A9$(\1!%*D\M2&A4NM=+/QRP;L4[C%F_:(=;&O!&R>+*'L- M':R"4TGGGA32:]J556"(W^<0E@>I(]\ JM&(K%"'$G$?AC!85=$*=3T1O^WA MT#['DY6$#;M,TZ0QA@WKXO=\9"/-NS81LS2;5@R;"M3@U:O411&!5F_#:93_ Q\0YF)RBIFRF&]<,QOK-3[T8@!;S.=3/^*T(N& F4:Y_>VM( M'0=_W46X%T@.&'R [HZ%65APC(":))WX<0@/8X:',3Z%P0].8"K"HZ4AHZ8X M S<+463V2V')PV F$JV2:7.E^LR0AG!7.)Z@BP(010HF9+S 12 0)[R/GNNX M-GB ;#R"R671E> MYUGV9<1L$2X"KR".WB&&';#U]/8C)GUMTL;(P\(:MK<"BY"Q)":SZOZ.&?I0 M>&X81,*U.? =3TX#)FU9%N%C,>AO"=^.!%T[T4*X=XU**8[)*BK\3.!__5>( MR@)3E,S)4S2PFCW V06LXN^0:?B8<4"F<,$1FQ2TT7 D"]JG/#,$O10D^Z[E MFAKW\;E(9^C[&TSK,S]BT'4Y<"Z7$U@C)N,,P!3X74RB8S&]R74-616<-P[" M# 1ODGRV'H!P['CH1!'C"I #03P.BD9<5H3W_.K\%I +'61LS2/K^/86$BG# M> ;&\4Q+(,)&@8HH"!]T+PRJZ7@J87JBRYAL;_FA MFNG8(I4M?YM*F\;NHBD@26H K.7+/-5R#0W6A1G7A44 ;KSYQ9Q!N2!N$PT5 M(D]1GF!<"3OB6:P:H_*,H. MS$Y,2WB"LEQZE9Z$GEVG1G;:U?('G/6"VC"*LN='Z; #$"0781.'0#,O\LK7 M+7RM(G.F4"3>B@ 9M,98=$F2_+^R[%L@ FX^E2*P7U1Q*T MGFH)_6U,XF1BN80/!!5C;^ #X$F0/RYRB*$+%L44Q1,,T9F1RO:69L'$.)*( MOCOTELGSZ7/'V$=X09(*RW)'FG>)GZPX()9K/S%7," _#5V":6_0A[FM_O4C M?WN_(W]O$OG;W.\ U4\:IV@#FK;T0=P$COT"0;X7SC[]C4" +OV,0%I-0+5R4^2F6>49<[:G[ MWZ."Q"]94V@$) AAH,&K9O ;!F]F>\8QX=P?JY!S/"F0YYPWBXASKAH^Q5/D M%,Q@C9R *\A \]MD,^@.?[CZ2%IA$;[W YXX654@)\QD6,6"%QQR9I _Z7!T M"-^\B@,4<3;#NO)?,-GQ',MC_Y TI8=:(.=X)=2[,41^ :O@Q55R@8J(%/[< MKSB @S][7=Q^WH\+'QS?B#(L<=53X$>)V>GXRW>G=E9ZK/[=ZN;[J=P[[^7VAZ?ZB7*ZF[+J MRO7?WQ[5Q\87-F*5J^^9??TT?=R\_C@:7XWMVPO[HK9?4?7F'57&?S=MWOS; M;&:/!_T]-OS[.C,LCWOCP<=,WN+ECU=.Z[Y]^KEU<%(:R:OZC.SFKIZSL]?67_-YUW]PW'NOY MD7HY&?>S>Y][]>:7+^WK?*V=/FX]?3W">)NO\#4$L#!!0 ( $PY M\U0$+$RFTQ +=% 6 =&TR,C(Q,S0U9#%?97@Y.2TQ+FAT;>U<:V_; MQK;]+D#_88YQ3I DB+93>HX;G#DR&[=Z\2&K3;H_7(Q(D?2U"2'F2$MZ_SZ MN_:>(44IMO.HT^,4+8JFXF-FSWZN_6#V?QJ_.7G5;NW_=#@2'&.E5.O%4+<6Y2F77\ MA8ZX4%9/M_ B7CVKWBO4==&5B9YE>\+JV;QX*5)I9QH_^UNO]@]>'5[/]407 MXL6+WF#_Z0$(.=M8HO'\HVSB\I=W/K)__.9'<7'^&ENGV]O;@YWOGL6#_U/7 M+UYT!SJ=]?N#WN_Y;$L,3\8_;&U]V7:?RHS&6?%H_Z5H7, MFC*+NY%)C-T3B[DN%$@[.GT[;F[9=?H_RN_+K!M>R5@E[=;97-I41JHL="03 M)X99AN4BT#7&'K+05TH,\]R:*YD(,Q4GO[PY_^U_'Q46K[\4CYV)=9D*<[V< MR$(]$5X*M#EM HI5%JNX:U6BI%/"6*SB2I>KS&F3W2RS/XE#![6(_HM$W"FF M+AD4\_)7+!B#P4X4WMACF*KO V+S9-/D\B\?BM=+%\OR>& MOXY.GG2$%!-M\K4'16327&9+,351Z50L3"8@ALQ-C4U)**F*=:2S()/ZEDC@ M0\"%PL1R"67U_B6&)LN"U?F7WD5/'!D3LR:/;#D3PQ@K:I8RW(1X?#0:/A%S MZ<0,JQ;T3EKBDZUW:K=T MUCCLFI(*#1G 3Q(/8^URXS2?&A;,3Y]).JUX:WI>NKN=[W<&G1?/=\1C6O%1 M$K\OSEA!MI+JRZ$Y47$"'\2)$6.@9BP,4DUS+1%9DKDW\1JY[*5"?+O8]M\($'" )_!P[.)?@)+D=S2%>*R&IOJE@8\C*9@IJZ MFXPE,ME4V_1+XHG7ZY5DVJV5:#I!];"DCL6/5LW$2%]I'.;U7*NI.+Q64@YR4M^\KA7U7/I*>8S])?*[L"%O,] 02@5EK$$MV?$5> M8M,@Q&EI!8,M-C"HY*4BKCB%9^;D>RH6!%Z#@0N5)-W*UY!'-;"]O"@M] 'Q M6)/8P5H'J2@BBD]R"V$X4UZY ^]S%G@(#B.EI['R1+'O\3Z 5MOI=_K]?GVP M$*-ZX@NM9.L51$*$YA5"(-]M9\CX!X7.' M]2>W*J>E2>T1 E-E(VB-2"3"V+P7%+["O-^B9WI'VG2#CT#\% [VBNC7$56^ M ,V![RATQEPFI9B:)#$+YGG$_.Y UE%2QOX! ]C/P17JM&9T#=#6C$D;THE5 MI"E58%&X.0Q)09$XNN"P\%)DBL5"J6SU#CWJQ;/R6GM?3S3CX<')H7A]>')R M-AR-CM_^^,-6?XM_7YP-7U>_WQV/QC_]L#7H]_^U]:44= N3,Q7UA8DI"I.& M:[?'GO%YM>65LNQ?*]2-%2GMWA^/JB<6.B[F6+&W_4QGE.2.1Z_NN'VKP5XL MTXE)P*U4Q[$I5B;BU_O2@+CUZ@A!*@X5B$_\1\*%LW=JHK 1 4P=%>*U*6U1 MHY;Z,G1G!&R]8 >8-5W#CD?7A&D_CPZ8$%;G;1IX34RM2<6MP&Q($0L$&ALC M8'I 6AE?6&!N$MS[/%K@%>\BARXVR*BB)BQ,QW 2].Q\(0/*W;#:SR-DA2QR MJTD(9L,-]]94Y^GXG/Y#1O>W0?\E#/J,(RQ4^O/TQFM>E$B=4DR"U98<@,1< M\6KB<4"0;X"'L&UUO4Z/','F,B'4AZ6&Y:QTA5<%Y%>?1TMP!U5*ZST*D,.5 M-J5+.#_D!(SR0Q5S*A;L&=IN08/?UWCW5&6#WAZ_Q,5P/LXN[V_C^6L;S^L: MC7V>GERJ)0.V*R0 6)^R;2P4Z;S.ZM=]>A/5Y8G,,OJ?*F;Z1SU2YO<_.P+0 M*B$*^%!D#5*RE+$/5!BAW99XGRS];Y;\B-C^0H=*V MRNZJG(MSD_G20682_*ZRO0JJU_F73T(+4Y"$/LS7?%SG#%CA:9(G7*7/ST*1 MZSI74>'JZIJ>!J6@O, G=VO5'DI^130WR.]90>KLU964%+/>$,)8);#4'V#_ M>#BZ6"L"]<289%]:2U07"RS9S:@3!)?*&&ZU1IVCM MBHE.$G_J%&"#>1M.<\U/8MW!\[74M">.J1 5MSE8ZU2$#6(JXY,2:SI%0 M;L^)KG3.0!OHP%PB(%^3U-D[+]9NQ.FVME*M9TJD-2&=B5>#XYTZO7VL;O&5).>\#KEPVNIG_Z';% MD59)O"?.Y$R]Q//O2Y5%5( 4W6YH_NZ/CG]=;WOZ>#S8OB$@/^> S("GOG:0 MP.F) 39W)M$Q"%@[0Z/D>7.?Z!- @#_4_E.0>@/5$ZC=9=<7?O8@>SIJ<]'G M-RQ*IVM2VN#A#9LU./F46.FY]T#%_T=[WP_H*/=4:K^[>SR MW]I!FFWPKWJ"6XEHM)ZRS5Y3NW5WLRE! +)RQEBPM(0;$=A500VXF%J)E _A MB25\2#3/L.ULR3$E5E3F]H5O0C#R4F5L4%7S/^AD,;;91"EWMJH>>%WX M4T4$$/2&X&5=E>G76(@QB/)AE"M)%^/NZ5OP3%/6((4%NTT*901B+75QR+S^8T,+)3+4,U?.E_L(P%##PI^PZIB&^I[FCFY5 M'2\SQC18WX-SJRJ4@RU6&BF+ I)TOD:2)"09.JU"(E?R:8 "E?,M?>N-( CC M+Z6R/R-7A&@KI1WL>@D*VIT+XC*%2R7JOW"/L;TYAODX@ M/<4S7YXB;PG\3[W.M=A'@<4D'+;S7&5+RYB49K9;MTZZ-()764F M@7KDS6[,X'MF]WJM*J21\J'U"9X+FYS,>E!H2Q+O*@M I_7"@SU%!% MUJF;\;"J3IA<9=U$(FGG&'UZ?K@:\W!%&9-B0+)4$, KY'A""GRE(6)0MUCT M+(V56#B&5>W&OXI(\O %\ F _HXAN7L=%'W 3F[KUN'@#R<%_;C8'Y@5%!^. M"OIQ%O9.TD^O4-T9CTHJ[M+;&E[JRD\K.).4]90':7F,?" Q>>4V>:-0'N- M+./85C RFB,$JVR&M>ORU!2'\!ZS+CLVP+^?*/$45O<3A&"?:\!]QCRGVUD5 M2V_*:3X2U3^2TK1;]YO3W#B=UP@H'M]^F.RT6Q\&EAO]1^Z'O]F-5#'NBT,% M>2')^DD^Y];5FNK\\!T3^Y_7DC69Q#S2+DJ,HV&L8NK'IQZV9QI3W39GLZN^!*B-.O1HP\1>-PF'<_7A0KO6:UL(92'%(LV] M4)S^!(C__;""J11[6T,_S#%XL>,GNM9?&1S>\,KA-7P#S3ZLWOV.FQ%. M<4'B%EJ%;V20_9'E3DN>I_/E:QF&H[AH/G6<_=+OU2Q[1YC)[T0;STN'U+%# M&-UW'_#_U&C+J-75;B%K8!N#>7?(1SBND7=6X Q>A/L7%R6@TQTT!U& ,H0_ M&G8A")CH5/.@M?$0%CZ!1[PXY8R4SHNZ1=ANU4BRGAPAQ+O>U0.^]2M5*7&X M'7H)=8:+U-[88F-HKUKS8U-B((5AT.:K@?H[)L76VEK<\W$&7C""KA+;;^<> MC;51\3^F#L%4E@V7$-NN'F)>PN;%T/7 M9?.RU[+-JT1QK;&;-WU4CBXWK\]*1#'2JXWK=8?XP\U#*V7S.OCY>X,J:H3Y M&YFZ+@3-ZE;V[4LYD%,B*;]A;^%UOFH!9VK&,9]CMU5@[6,O,VJ (>=^\LVW M5[;_;J_\W5YY\.T5PKYW.$2*('51;-4G)RN6SI6IA]#D(J4/-RG G&@$]PFE M9WX0'CO19SR)BF>JNC IW0J6(J>U5?,["]\4+7Q92_MI2>D J> =>N(GLR!@ MW5E;Q4>,YC(T %]R'*9 TJSS6NTNO3_BSRID"&4=[X^J2)!QI;JTY$!#RA$5 MI4SJP%?YLT8@!$7MUFT'HUC!,3G6-#\AB)_6SU#7\;9:BRKI*LW]- 7XZ>Z. M_4#L(,[8D!MQN&FW(DFA:X-J&A?U^_.F34S#PVQW*T7 &)Y68B,?DCX$LX74 M&6,NH,'(ZHDG' ^N@L4YWJ@HK;\P475S_TS:,+=W7'T4AWW%8%BIS)#[[X#2 MU+4GM0243D/UJ-_]GSHEXN$%_F)5C !RTHFRC7G [?[VH+/ZOH&^E8E7$P<- M\$A'JP$D\$VJ.931QHT>RN!Y52+DR%=.?"&V$!>'KVEQ<- ]Z(AV=+NX@47E M)P#CD>%<*%EVQ-*4]$$ M#5_0V]R^@$91<1LH7+/Y^?K]KKO=PHNDBI:"!0Y*XX4PO+U[ M3C%Y0#:#*HQA-#(S][CT!;QC)NH#G*LD9%[!-631?3*_.D@O'.3?CK;7UA\?N/*\4;&67TMS?I03"\R72/J\4,_N<>5SA1CQ M>JY2^@!D>8\+SV9$Z;^!19*H6O[>]:._\T1L?_>BN_U\=_=!Z\TE^\XO\F%OH+6_X?4$L! A0#% @ 3#GS5*DI MFU-# P *0P !$ ( ! &%V9&PM,C R,C W,3DN>'-D M4$L! A0#% @ 3#GS5&V'L-W_"@ ;(< !4 ( !<@, M &%V9&PM,C R,C W,3E?;&%B+GAM;%!+ 0(4 Q0 ( $PY\U3\Y.H[5 < M +U8 5 " :0. !A=F1L+3(P,C(P-S$Y7W!R92YX;6Q0 M2P$"% ,4 " !,.?-4L*U/#UL8 ".@ $@ @ $K%@ M=&TR,C(Q,S0U9#%?.&LN:'1M4$L! A0#% @ 3#GS5 0L3*;3$ MT4 M !8 ( !MBX '1M,C(R,3,T-60Q7V5X.3DM,2YH=&U02P4& 2 4 !0!) 0 O3\ end